Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial.

Kim HR, Oliva M, Salas S, Wong DJ, Even C, Kim JW, Kang M, Wu SY, Lauche O, Ahn MJ, Yang MH, Lien MY, Metcalf R, Clatot F, McGrath M, Webster M, Assaf JD, Rivas AS, Bernsdorf M, Billan S, Kaczmar J, Grose D, Jankowska P, Jelinek MJ, Ciuleanu TE, Vieira C, Dutcus C, Okpara CE, Wang G, Bidadi B, Gumuscu B, Harrington K

Open source

DOI: 10.1016/j.ejca.2026.116824
Published: 2026 Jul 26
Container: European journal of cancer (Oxford, England : 1990)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ejca.2026.116824,
  title = {Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial.},
  author = {Kim HR and Oliva M and Salas S and Wong DJ and Even C and Kim JW and Kang M and Wu SY and Lauche O and Ahn MJ and Yang MH and Lien MY and Metcalf R and Clatot F and McGrath M and Webster M and Assaf JD and Rivas AS and Bernsdorf M and Billan S and Kaczmar J and Grose D and Jankowska P and Jelinek MJ and Ciuleanu TE and Vieira C and Dutcus C and Okpara CE and Wang G and Bidadi B and Gumuscu B and Harrington K},
  year = {2026},
  journal = {European journal of cancer (Oxford, England : 1990)},
  doi = {10.1016/j.ejca.2026.116824},
  url = {https://doi.org/10.1016/j.ejca.2026.116824}
}

RIS

TY  - JOUR
TI  - Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial.
AU  - Kim HR
AU  - Oliva M
AU  - Salas S
AU  - Wong DJ
AU  - Even C
AU  - Kim JW
AU  - Kang M
AU  - Wu SY
AU  - Lauche O
AU  - Ahn MJ
AU  - Yang MH
AU  - Lien MY
AU  - Metcalf R
AU  - Clatot F
AU  - McGrath M
AU  - Webster M
AU  - Assaf JD
AU  - Rivas AS
AU  - Bernsdorf M
AU  - Billan S
AU  - Kaczmar J
AU  - Grose D
AU  - Jankowska P
AU  - Jelinek MJ
AU  - Ciuleanu TE
AU  - Vieira C
AU  - Dutcus C
AU  - Okpara CE
AU  - Wang G
AU  - Bidadi B
AU  - Gumuscu B
AU  - Harrington K
PY  - 2026
JO  - European journal of cancer (Oxford, England : 1990)
DO  - 10.1016/j.ejca.2026.116824
UR  - https://doi.org/10.1016/j.ejca.2026.116824
ER  -

APA

HR, K., M, O., S, S., DJ, W., C, E., JW, K., M, K., SY, W., O, L., MJ, A., MH, Y., MY, L., R, M., F, C., M, M., M, W., JD, A., AS, R., M, B., S, B., J, K., D, G., P, J., MJ, J., TE, C., C, V., C, D., CE, O., G, W., B, B., B, G., & K, H. (2026). Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial.. European journal of cancer (Oxford, England : 1990). https://doi.org/10.1016/j.ejca.2026.116824

Source records

pubmed · retrieved 2026-09-25T10:23:40.222Z